They Asked Me to Shill Their Peptides. I Sent Them to a Lab Instead.

They had no idea what they were getting themselves into. SPONSOR LINK: PlaudAI https://bit.ly/3OAlAO9 15% off with code: CARNEY Notepro Amazon: https://amzn.to/4t6t6hE CODE: CARNEY15 Get Your NON-ENDORSED Peptides Iron Peptides: https://ironpeptides.is/?ref=vkdoeywl Discount Code: scottcarney Get Early Access on Substack https://sgcarney.substack.com/ Join the Discord:   / discord   Join this channel to get access to perks:    / @sgcarney   Scott Carney Homepage: https://www.scottcarney.com Patreon:   / sgcarney   SPONSOR THIS CHANNEL: (Rate Sheet) https://drive.google.com/file/d/1WZcG... 00:00 - The Sketchy Email 01:49 - The Pitch 03:09 - SPONSOR: PlaudAi 04:52 - What are Peptides? 06:36 - Missing Science 07:42 - Legal Loopholes 12:01 - Fact-Checking 17:05 - The Grift Economy 20:18 - Lab Testing 25:16 - Inside the Scam 32:16 - The Final Verdict DISCLAIMER: (Updated Mar 2026): All content herein constitutes commentary and opinion based on investigative journalism conducted with (i) publicly available documents, (ii) interviews, and (iii) other verifiable sources. References to “scams,” “fraud,” “theft,” or related terms should not be taken as definitive findings of fact or legal conclusions. Facts, evidence, and independent analysis are used in this program to draw strongly opinionated conclusions, but it is important to draw a sharp distinction between the facts and evidence presented, and the opinions drawn based on such material. No statement can or should be interpreted as a categorical declaration that any person has violated civil or criminal law unless a court has so ruled. Viewers are encouraged to examine the cited materials and reach their own conclusions. Anyone featured who believes a statement is inaccurate or incomplete may contact us at our business email with supporting documentation under the SUBJECT: “CORRECTION REQUEST”. We will promptly review substantiated concerns and, where appropriate, issue corrections or updates. ©Foxtopus, Inc (2026)